Orchestra BioMed Holdings Inc
Orchestra BioMed Holdings Inc (OBIO) Covered Calls
As of September 25, 2026, OBIO has 2 covered call opportunities in the coming three months. Return ranges from 26.9 to 30.3% until expiration. Annualized return ranges from 74.6 to 446.1%. The nearest expiration is October 16, 2026. Maximum potential profit is $180.
Read more
Running OBIO covered calls helps you generate consistent income from Orchestra BioMed Holdings Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Orchestra BioMed Holdings Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best OBIO covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if OBIO stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling OBIO covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Orchestra BioMed Holdings Inc covered call is worth writing.
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease.
Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Income-focused investors, long-term OBIO holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling OBIO covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Orchestra BioMed Holdings Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile9.52% Subdued
- Market cap (M$)358
- 52 weeks high-8.18%
- 52 weeks low150.00%
- Analyst recommendationStrong Buy
1.00 - Target price$12.14
104.03% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-09
- P/E—
- Future P/E—
- EPS (ttm)-1.00
- EPS growth next 5 years4.97%
As of September 25, 2026
| 2026-10-16 | 22 | 7.50 | 26.05 | 0.05 | 0.40 | 160.00 | 26.89 | 446.14 | -0.84 | +0.25 | 222 | 0.35 |
| 2027-02-19 | 148 | 7.50 | 26.05 | 0.25 | 1.50 | 180.00 | 30.25 | 74.61 | -4.20 | +0.46 | 20 | 1.25 |
As of September 25, 2026
Sell covered calls with the data behind you
Find the best OBIO covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→